Payer denials are not new to revenue cycle leaders. But DRG downgrades represent a particular kind of threat: one that often arrives quietly, weeks after discharge, buried in a post-payment adjustment. By the time your team catches the downgrade, the revenue has already walked out the door. 

This guide walks through the DRG downgrade appeal process from triage to escalation, with a focus on what truly moves the needle for revenue cycle teams. You will learn how to identify the highest-risk DRGs, build a defensible appeal, and put the right people on the right denial type. More importantly, you will learn how to stop treating appeals as one-off firefighting and start running them as a systematic revenue recovery function. 

The numbers tell a stark story 

According to the American Hospital Association, Medicare Advantage claim denials increased 55.7% between 2022 and 2023, while commercial denials rose 20.2% over the same period.  

Hospitals spent nearly $18 billion in 2025 alone fighting to recover payments they had already earned. For a revenue cycle operation running on thin margins, that is not sustainable. 

The good news is that this is a winnable fight. A 2024 Premier Inc. analysis found that more than 54% of denied claims are ultimately overturned. The hospitals recovering revenue share one thing in common: A systematic approach to appeals.  

Why DRG downgrades are different 

An outright denial is visible. A DRG downgrade is not. Payers conduct retrospective reviews and reassign a lower-weighted DRG, often weeks or months after the claim was paid. The result is a quiet, compounding revenue drain that can be easy to miss in a high-volume environment. 

The downstream consequences extend beyond individual claims. Repeated downgrades suppress your Case Mix Index (CMI), signaling to payers and regulators that your hospital serves a less complex patient population. A lower CMI reduces prospective payment rates, weakens your negotiating position with commercial payers, and can invite additional scrutiny. One downgrade is a billing dispute; a pattern of downgrades is a strategic liability. 

Medicare Advantage plans have been the most aggressive in pursuing these adjustments. What many hospitals do not fully leverage is that CMS rules require MA plans to follow standard Medicare coding policies and ICD-10 guidelines. That is not just regulatory background; it is a direct line of defense in your appeal. The threat has grown more sophisticated in recent years. 

Payers using AI to downgrade DRGs at scale: A growing threat 

Payers are increasingly deploying automated algorithms and AI-driven audit tools to flag and downgrade DRGs at scale, often before any human clinical reviewer touches the claim. 

The AHA has specifically identified machine learning algorithms as a driver of denial growth, noting that poor applications of these tools result in automatic denials without consideration of a patient's individual clinical circumstances or review from a clinician or plan medical director.  

For revenue cycle teams, this changes the nature of the appeal. When a denial originates from an algorithm rather than a physician reviewer, the response strategy is different. You are not rebutting a clinical judgment; you are challenging an automated decision that may have applied rigid criteria without accounting for the full complexity of the case. That distinction matters when building your appeal, selecting your escalation path, and deciding when to request a peer-to-peer review. 

Know where you are most vulnerable 

Payers do not audit randomly, but rather they concentrate reviews on high-weight DRGs where a downgrade yields the largest financial return. Understanding which cases carry the most exposure is the first step toward protecting rightful revenue reimbursement. 

The diagnoses that consistently draw the most scrutiny include sepsis, acute respiratory failure, acute kidney injury, severe malnutrition, and type 2 myocardial infarction.  

Type 2 MI is frequently targeted because demand ischemia is often documented as a secondary finding rather than the principal diagnosis, and payers require specific documentation linking the underlying cause to the MI designation. Severe malnutrition denials turn on whether the record explicitly supports the criteria for that severity level, including the specific indicators the clinician used to arrive at that diagnosis, such as weight loss, reduced intake, or functional decline. 

In both cases, a concurrent CDI query during the encounter is far more effective than a post-discharge appeal. Trauma cases and patients requiring ECMO are also high-risk, given the complexity of documentation those cases demand. These are not obscure edge cases; they are common high-acuity admissions that appear in nearly every inpatient facility.

The financial stakes per case are significant 

Overturning a sepsis downgrade can recover between $3,000 and $7,000 per claim. Multiply that across volume, and the revenue impact becomes clear. 

Certain documentation patterns invite denials even when the clinical picture is straightforward. Inconsistent language across providers, a single MCC carrying the entire DRG shift, and a short length of stay paired with a complex diagnosis are all triggers that flag cases for payer review. Identifying these patterns before billing is far less expensive than appealing them after.

The distinction that determines your strategy 

Before building an appeal, your team needs to answer one question: What kind of downgrade is this? 

There are two distinct types, and they require fundamentally different responses. Getting this wrong is one of the most common and costly mistakes in the appeals process. 

The first is a coding-based downgrade. The payer disputes the ICD-10 code assignment itself: the sequencing of diagnoses, the selection of a CC or MCC, or the application of coding guidelines. These appeals are built on ICD-10-CM Official Guidelines, AHA Coding Clinic references, and UHDDS definitions. A strong coder and CDI specialist can lead this defense. 

The second is a clinical validation denial. Here, the payer is not challenging the coding; it is challenging whether the clinical evidence in the record supports the diagnosis at all. A common example is sepsis: A case documented under Sepsis-2 criteria may be denied by a payer applying the narrower Sepsis-3 standard. 

 ICD-10-CM Official Guidelines and AHA Coding Clinic do not require Sepsis-3 criteria for diagnosis coding, meaning a payer applying a Sepsis-3 threshold is imposing a standard that exceeds CMS coding guidance and is a contestable overreach, not a legitimate basis for denial. 

This type of denial requires a physician advisor to lead the response, with a clinical narrative that addresses the acuity of the case in medical terms. 

Some denials combine both elements. Recognizing that early allows you to mobilize the right resources without losing time.  

The appeal process, step by step 

Step 1: Triage fast and protect your deadlines 

The moment a downgrade is identified, the clock is running. Appeal windows vary widely by payer, from 30 days to one year, and a missed deadline forfeits your right to dispute entirely. Deadline management is not an administrative detail; it is a revenue protection function. 

For Medicare fee-for-service, the process follows a five-level path:  

1. MAC redetermination  
2. QIC reconsideration  
3. ALJ hearing   
4. Medicare Appeals Council review  
5. Federal court 

Medicare Advantage plans are required to provide the same five-level structure under CMS rules. For commercial payers, appeal rights are contract-specific, so reviewing the payer agreement and the explanation of benefits language is an essential first step. 

Your triage process should identify the downgrade type, assign the right team, and confirm the deadline before anything else moves forward. 

Step 2: Put the right people on the case 

The appeal team should match the denial type. For a coding-based downgrade, that means your lead coder and CDI specialist. For a clinical validation denial, a physician advisor is not optional; it is the foundation of the appeal. Payer medical directors respond to peer-level clinical arguments in ways they simply do not respond to coding citations alone. 

Before launching a formal written appeal, consider requesting a peer-to-peer review with the payer's medical director. This step alone resolves a meaningful share of clinical validation disputes and avoids the time and cost of a full written escalation. A revenue cycle lead should own the process end-to-end: tracking deadlines, coordinating team members, and managing escalation timing. 

Step 3: Build a complete appeal kit 

One of the most consistent findings in DRG downgrade cases is that payers issue denials without having thoroughly reviewed the medical record. Do not assume they have read it. Submit the complete record with your appeal and make the relevant clinical evidence impossible to overlook. 

Start with a clinical timeline: from the patient's ED presentation through labs, imaging, treatment decisions, and clinical course. Then layer in the objective markers specific to the diagnosis in question.  

• For sepsis cases, that means SOFA scores, lactate trends, blood cultures, and qSOFA findings.  

• For respiratory failure, include ABG and VBG values, FiO₂ levels, PEEP settings, P/F ratio, and SpO₂ documentation. 

• For acute kidney injury, document creatinine trends, urine output, and baseline renal function for comparison. 

Pair the clinical evidence with authoritative coding references: The ICD-10-CM Official Guidelines from CMS and relevant AHA Coding Clinic guidance. Then pull the payer's own medical policy and identify precisely where the record meets their stated criteria. Finally, annotate the denial letter directly, addressing each stated rationale with a specific, documented rebuttal. 

Step 4: Write an appeal letter that works 

The appeal letter is where the case is won or lost. Structure matters as much as content. 

Open with the regulatory grounding: the applicable ICD-10-CM coding guidelines, UHDDS principal diagnosis definitions, and, for MA plans, the CMS requirement to follow standard Medicare coding rules. Establishing the governing framework early tells the reviewer this appeal is built on policy, not preference. 

Then tell the clinical story. Narrate the acuity of the case: what the patient presented with, how the clinical picture evolved, what treatment decisions were made and why. A list of diagnosis codes does not convey complexity. A well-constructed clinical narrative does. 

Address the payer's denial rationale directly and specifically. Ignoring their argument signals weakness; dismantling it signals command of the case.  

For clinical validation denials, lead with the physician advisor's attestation and let the clinical evidence carry the argument. Throughout, keep the tone professional and factual. Adversarial language rarely helps and can invite dismissal at the first level of review. 

Step 5: Escalate deliberately and track everything 

Most hospitals stop appealing after the first denial. That is exactly what payers count on. The data supports persistence: Over 54% of denied claims are eventually overturned, with commercial payers reversing more than 60% of initial denials. The revenue is there to be recovered. 

Know your escalation path and the timing requirements at each level before you need them. ALJ hearings and external reviews are not last resorts; they are legitimate tools that frequently produce favorable outcomes for well-documented cases. 

Treat every payer interaction as part of the record: Log dates, contacts, responses, and outcomes. Over time, this data becomes your pattern file, revealing which payers are systemically downgrading specific DRGs and building the case for a broader response. 

Note: Under CMS-4208-F, which was made effective January 1, 2026, once an MA plan approves an inpatient admission, it generally cannot reverse that approval based on information gathered after the fact. Plans may normally reopen only for fraud or obvious error. Hospitals that are not aware of this protection may be conceding mid-stay reversals they no longer have to accept.  

Shifting from reactive to proactive 

Winning appeals is important; not needing to appeal is even better. 

The most effective strategy is pre-bill clinical validation review for every high-risk DRG before the claim goes out. CDI involvement should be concurrent, not retrospective; documentation gaps are far easier to close during the encounter than after discharge.  

Engaging physicians directly, and showing them specifically how their documentation affects reimbursement and audit exposure, is one of the most effective CDI tactics available. 

CMS updates DRG logic, CC/MCC designations, and documentation requirements every fiscal year through the IPPS final rule. Annual training for coding and CDI staff on those updates is not optional if you want to avoid preventable denials.  

The PEPPER report, a free CMS benchmarking tool, allows hospitals to compare DRG coding patterns against national norms; coding within normal ranges is both a compliance indicator and a defense against payer scrutiny. 

Track denial trends monthly by payer, DRG, and diagnosis. A pattern of downgrades on a specific DRG from a specific payer is not a coincidence; it is a signal of systemic audit activity, and for public payers, it can precede recoupment extrapolation across a broader population of claims. Getting ahead of that pattern is less expensive than responding to it. 

Building appeal kit templates for your highest-risk DRGs removes the friction from the process. When a denial arrives, your team should not be starting from scratch; they should be activating a documented workflow. 

The bottom line 

DRG downgrades are not inevitable losses. They are recoverable revenue, and the hospitals capturing that revenue are the ones that treat appeals as a systematic revenue protection function rather than a case-by-case administrative burden. 

Every uncontested downgrade is a permanent write-off. Every pattern left untracked is a compliance risk. And every dollar recovered through a successful appeal is proof that the investment in a disciplined DRG audit process returns far more than it costs. 

About the author 

Kelsey Taylor, BSN, RN, is the Senior Director of Clinical Denials at EnableComp, bringing over 10 years of experience in healthcare management and clinical operations to the role. Her background spans clinical quality, care management, and product management, giving her a well-rounded lens on how revenue cycle, training, and clinical operations intersect. She's passionate about empowering teams to deliver patient-centered, impactful results and frequently speaks on topics like DRG revenue integrity, complex revenue recovery, and denial prevention strategy. 

You don't need to be convinced that denials are a problem. You're living it.

In a recent survey of hospital and health system executives, nearly 81% reported that rising denial rates are a major stressor. The frustration is real, and so is the revenue walking out the door. 

What makes the problem more difficult is that most providers don't have a clear view of what denials are actually costing them. Blended metrics that lump routine administrative denials together with complex clinical disputes can make overall performance look stronger than it is, while significant revenue leakage goes undetected. 

Then there's the cost of fighting back. Appealing a denial isn't free, and for high-volume environments, the math on whether to pursue a claim isn't always straightforward. Meanwhile, payers are getting faster and more sophisticated, and most hospitals are not keeping pace. 

This article cuts through the noise with the denial statistics every CFO should have on their radar: where revenue is slipping through the cracks, why the full scope of the problem is so difficult to see, and what leading health systems are doing differently to get ahead of it. 

Denial rates are rising across every payer type 

Denial pressure is broad-based, with strong independent signals from Medicare Advantage and the ACA marketplace. A Health Affairs analysis found that Medicare Advantage plans denied approximately 17% of initial claims, with 57% ultimately overturned. 

KFF's analysis of CMS transparency data found that HealthCare.gov marketplace plans denied 19% of in-network claims and 37% of out-of-network claims in 2024. The same report found that administrative reasons accounted for 25% of in-network denial reasons, reinforcing the need to separate preventable denials from more complex payer disputes. 

For hospital finance leaders, rising denial rates are not only an operational problem; the dollars behind those denials are a cash problem. When those dollars remain unresolved or fall out of appeal workflows, the result is revenue leakage. 

Blended metrics can hide revenue leakage 

High-level denial reporting has value, but it can mask leakage.   

While the cost of processing a routine claim is typically around $7 to $10 across payers and providers, EnableComp, which specializes in RCM complexity, estimates costs for processing a complex claim can be three to ten times that, with some claims costing even more. That spread matters because complex denials often require clinical review, coding expertise, regulatory knowledge, and payer-specific escalation. 

When standard and complex denials are grouped, high-volume administrative recoveries can make performance look strong, while a smaller set of complex cases creates disproportionate exposure. 

The price hospitals pay just to recover what they're owed 

In 2025, U.S. hospitals spent $43 billion trying to collect payments from insurers for care already delivered.  

The average cost to rework a denied claim is between $25 and $181. Overturning claims denials costs hospitals nearly $18 billion in 2025 alone.  

For high-volume denial environments, those rework costs compound quickly, leaving revenue cycle teams to weigh whether each claim is worth pursuing. It's a calculation that doesn't always get made accurately or at the right scale. 

Recoverable denial revenue is slipping through the cracks 

Only 11.5% of denied Medicare Advantage prior authorization requests were appealed, and of those, 80.7% were overturned. The appeal process works, but resource constraints and ROI concerns quietly push recoverable revenue off the table before the fight even starts. 

For hospitals operating under margin pressure, unworked denials become write-offs. Complex cases routed into standard queues can age past the point of recovery, and reimbursement for delivered care provided never arrives. 

Silent denials 

Not every revenue loss shows up as a denial. A silent denial won’t show up as a rejected claim by a payer, but the submitted claim is not fully paid either. 

DRG downgrades, Emergency Department (ED) level-of-care downgrades, and other underpayments arrive as payment reductions rather than formal denial notices, which means they often bypass the workflows built to catch them. For many hospitals, these losses are hidden in plain sight. 

DRG downgrades alone can represent significant dollars per claim. When a payer recodes a case to a lower-weighted diagnosis, the revenue difference rarely triggers the same urgency as an outright denial, even when the financial impact is comparable or greater. The same is true for ED downgrades, where payers reduce the level of care billed without issuing a formal denial that revenue cycle teams would typically flag and pursue. 

Silent denials are a category of revenue leakage that's harder to see, harder to track, and harder to recover. Many hospitals aren't measuring it at all, not because they're not paying attention, but because their denial management systems weren't built to surface it. If your team is only tracking what's formally denied, you're likely underestimating your total exposure by a meaningful margin. 

Payers are getting faster and more sophisticated at claim review 

Payers are using AI and advanced analytics to review claims across broader datasets and at faster speeds. A Stanford-led review  evaluated 21 AI tools active across utilization review and described the dynamic as an "arms race." An NAIC survey of 93 large health insurers found that 84% were already using AI in their operations. 

The question for providers is not whether to match payer AI with provider AI. Most organizations will not win an arms race based on technology alone. The more practical challenge is to understand how payer behavior is changing and direct expertise toward the claims that carry the greatest financial risk. 

The pressure is not always where hospitals expect. Hospitals can strengthen the mid-cycle with better documentation, analytics, and earlier intervention. But technology alone will not close the gap.  

Complex denials involving payer-specific audit patterns, post-payment adjustments, and clinical validation still require experienced review and clear escalation paths. For many organizations, working with RCM experts focused on complex denial categories is becoming a practical revenue-protection strategy.  

The next generation of denial management 

The next generation of denial management is less about adding another appeal queue and more about building revenue intelligence around claims already in motion. 

Leading organizations are treating denial management as more than a back-end collections process. The goal is not only to overturn more denials faster but also to understand which revenue is most at risk, where denial patterns are emerging, and where earlier intervention can prevent future write-offs. 

That shift matters because treating every denial with the same level of effort is not a strategy. The advantage comes from better prioritization, earlier intervention, and the ability to learn from denial patterns over time.   

What providers can do about denial-related revenue leakage 

When denial rates climb, the answer is not simply to work faster. The stronger strategy is to segment denials by complexity, recoverability, and financial risk.  Here’s where to start: 

Strengthen front-end processes to prevent avoidable denials 

Registration, data verification, and prior authorization errors remain common causes of claim denials. Real-time eligibility checks, cleaner intake workflows, stronger authorization tracking, and better documentation practices can prevent many routine denials before they reach the payer. 

Segment denial performance by complexity and financial exposure 

Separating standard denials from complex clinical and payer-specific denials lets revenue cycle teams track each category by dollar value, recovery rate, time to resolution, and aging. Specialized resources should be directed toward the claims with the highest financial risk and strongest likelihood of recovery. 

Invest in the right people and vendors  

Denial management depends on coordination among patient access, clinical documentation, coding, case management, finance, and payer teams. Complex denials often require clinical judgment, coding expertise, and payer-specific knowledge, making cross-functional accountability essential.  

Use technology to move from reactive to predictive  

Technology should help teams see patterns earlier, not just move denied claims through a queue faster. Hospitals need to understand which payers are changing behavior, which categories are growing, which service lines are most exposed, and which claims are most likely to recover before write-offs accumulate. 

The goal is to move from chase-and-collect to predict-and-prevent. 

The revenue you recover depends on the work behind the denial 

Denial rates are rising. Rework costs are increasing. Recovery is taking longer. Payers are also becoming more sophisticated in how they review, downgrade, and challenge claims. The hardest dollars to recover are often tied to complex clinical and payer-specific denials that standard workflows were not designed to resolve. 

That is the real cost of claim denials: delayed cash, avoidable rework, premature write-offs, and complex cases that never receive the right review. 

The organizations that perform best will not necessarily be those with the lowest denial rates alone; they will be the ones with the visibility, expertise, and processes to respond before recoverable revenue is lost.  

How EnableComp can help 

Most denial management approaches treat all denials the same, and that's exactly where revenue gets left behind. EnableComp specializes in the complex denials that are hardest to see, hardest to fight, and most likely to be abandoned before recovery. That means DRG downgrades, ED downgrades, underpayments, and high-value clinical disputes that require specialized expertise and payer intelligence that most internal teams simply don't have the bandwidth to build. 

The hospitals seeing the strongest recovery results aren't working harder; they're working on the right claims with the right resources. If your organization is ready to understand where your true denial exposure lies and how much of it is actually recoverable, that's exactly the conversation EnableComp wants to have with you. Contact us now.  

About the author 

Kelsey Taylor, BSN, RN, is the Senior Director of Clinical Denials at EnableComp, bringing over 10 years of experience in healthcare management and clinical operations to the role. Her background spans clinical quality, care management, and product management, giving her a well-rounded lens on how revenue cycle, training, and clinical operations intersect. She's passionate about empowering teams to deliver patient-centered, impactful results and frequently speaks on topics like DRG revenue integrity, complex revenue recovery, and denial prevention strategy.